The ACR Convergence 2025 data specifically showed additive benefit when GLP-1 agonists were combined with DMARDs
The differences among studies is primarily due to differences in methods that the researchers use to study the question
The FDA has issued cautions about reports of adverse events associated with compounded semaglutide, such as severe gastrointestinal difficulties and unanticipated side effects
"Some people will say things like, 'Oh, when I started regaining weight, it seemed like I just smell food, and I gained more weight.' That's an exaggeration, of course, but it can certainly feel that way given the pace of how quickly some people can regain weight." In addition, as with weight loss, many variables affect weight gain, some of which we can control, some of which we can't
Insurers may want to consider adjustments to their specific mortality improvement assumptions to reflect AOMs